Olivia Goldhill

Compass Pathways said Monday it achieved its primary endpoint in an early readout from the largest-ever study of psilocybin for treatment-resistant depression.

HHS secretary Robert F. Kennedy Jr. declared that the FDA’s “suppression of psychedelics” was about to end. Now he and his allies may be in position to do something about it.

MDMA therapy is facing an imminent FDA decision. Here’s what you need to know

Existing therapies don't work well for many people with PTSD, and no new drug for the disorder has been approved in more than two decades.

Shifting from topic to topic, with few connections, is one of several disjointed and occasionally incoherent verbal habits that seem to have increased in Trump’s speech.

The FDA said it’s investigating Lykos studies of MDMA treatment for PTSD. Key people involved in misconduct claims have yet to be contacted.

Despite an advisory panel’s strong criticisms of MDMA, the FDA’s favorable view of psychedelics suggests an approval is quite possible.

The psychedelics company oversaw a pattern of lapses during its clinical trials, according to former employees who spoke with STAT.

FDA advisers weigh the first use of psychedelic therapy for post-traumatic stress disorder, review safety and efficacy data from MDMA trials.

As Lykos Therapeutics seeks a landmark approval of psychedelic therapy for PTSD, it will face scrutiny from an FDA advisory panel next week.